Latest RH5 clinical trial shows promise

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

 

In our groups latest publication, Minassian et al. report that the RH5.1/AS01B vaccine against blood-stage Plasmodium falciparum malaria is safe and immunogenic in a phase I/IIa clinical trial. They demonstrate a significantly reduced blood-stage parasite growth rate in vaccinees following controlled human malaria infection and identify that in vitro antibody-mediated growth inhibition activity is associated with challenge outcome.

 

The graphical abstract is show on the right. Full citation:

Minassian, Angela M., et al. "Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination." Med (2021).